(MENAFN- America News Hour)
Kenneth Research has evaluated the current market opportunities in Recombinant Follitropin Beta Market in the healthcare industry for the forecast period 2022-2031 , which also includes the ongoing industry trends and innovations that will help industry players to attain their business targets. Apart from that, the inclusive data on market size, market share and forecast, growth opportunities and challenges for the market players, along with the worldwide analysis on regions- North America, Latin America, Europe, Asia Pacific and Middle East & Africa, has also been provided in the report.
U.S. Market recovers fast; In a release on May 4th 2021, the U.S. Bureau and Economic Analysis and U.S. Census Bureau mentions the recovery in the U.S. International trade in March 2021. Exports in the country reached $200 billion, up by $12.4 billion in Feb 2021. Following the continuous incremental trend, imports tallied at $274.5 billion, picked up by $16.4 billion in Feb 2021. However, as COVID19 still haunts the economies across the globe, year-over-year (y-o-y) average exports in the U.S. declined by $7.0 billion from March 2020 till March 2021 whilst imports increased by $20.7 billion during the same time. This definitely shows how the market is trying to recover back and this will have a direct impact on the Healthcare/ICT/Chemical industries, creating a huge demand for Recombinant Follitropin Beta Market Products.
Download Sample of This Strategic Report: –
According to the statistics by the World Bank, current health expenditure around the world increased from 9.391 % of GDP in the year 2011 to 9.896 % of GDP in the year 2017. Moreover, the statistics also stated that Tuvalu, a nation in Oceania region, had the highest expenditure of 17.143 % of GDP in the year 2017, followed by the United States, with 17.061 % of GDP.
“Final Report will add the analysis of the impact of COVID-19 on this industry.”
In China, the number of infertile couples is increasing. According to Chinese media, in 2018, more than 40 million people in China were infertile, with the incidence of infertility in couples of childbearing age increasing from 3% 20 years ago to 15% in recent years. According to the Global Burden of Disease, in 2017, the incidence of infertility was 2,705.66/100,000 in Chinese women and 879.32/100,000 in Chinese men. The common causes of female infertility include ovulation disorders, fallopian tube damages and endometriosis; the major causes of male infertility include varicoceles, infections, ejaculation disorders and anti-sperm antibodies.
The increasing incidence of infertility in China is attributable to the endocrine disorders caused by worsening environmental pollution, increasing life pressures and unhealthy lifestyle, the increase in the average childbearing age of women, and the damages to female fertility caused by induced abortion.
Infertility is mainly treated by drug, surgery and assisted reproductive technology (ART). The drugs are ovulation stimulants that apply to the couples who have no organic disorders. Surgeries apply to organic disorders such as varicoceles in men and blocked fallopian tubes and intrauterine adhesion in women.
If drugs or surgeries do not work or if couples have other indications, ART will be applied. About 20% infertility patients are treated by ART. ART procedures mainly include artificial insemination (AI) and in vitro fertilization and embryo transfer (IVF-ET, or test-tube baby) and their derivative technologies. They bring higher pregnancy rate than drugs and surgeries. As the success rate of AI is lower, some patients directly choose IVF-ET. And some patients turn to IVF-ET after repeated AI failures. At the end of 2018, more than 450 medical institutions were qualified to implement ART, of which 350 could implement IVF-ET and more than 40 could provide pre-implantation genetic diagnosis; the number of ART practitioners reached 10,000; the clinical pregnancy rate of ART in China was 40% and the live birth rate was 30% to 35%. China have over 200,000 newborn test-tube babies every year, ranking the first in the world.
In 2006, the Recombinant Follitropin Beta injection by Merck Sharp & Dohme became the first Recombinant Follitropin Beta product approved to be sold in China. In 2011, Recombinant Follitropin Beta (trade name: Puregon) by Organon (now affiliated to Merck Sharp & Dohme) was approved to be sold in China. And all the Recombinant Follitropin Beta products on the Chinese market are the products of Organon. The sales value of Recombinant Follitropin Beta kept rising after the drug entered China. It reached about CNY 126 million in 2017.
In China, Recombinant Follitropin Beta is used to treat anovulation (including polycystic ovary disease, PCOD) that cannot be cured by clomiphene citrate. It is also used in ART procedures such as IVF-ET, gamete intrafallopian transfer (GIFT) and Intracytoplasmic sperm injection (ICSI) for controlled ovarian hyperstimulation and follicular development.
As the incidence of infertility increases, the demand for Recombinant Follitropin Beta in China will keep growing. From 2019 to 2023, China's Recombinant Follitropin Beta market will continue to expand. In the next few years, Recombinant Follitropin Beta products by enterprises other than Organon will possibly be launched in China.
T opics covered:
– Incidence of infertility in China
– Status of China's Recombinant Follitropin Beta market
– Prices of Recombinant Follitropin Beta in China
– Major factors influencing development of China's Recombinant Follitropin Beta market
– Prospect of China's Recombinant Follitropin Beta market from 2019 to 2023
Request To Download Sample of This Strategic Report: –
The Market report answers the following questions:
What is the aim of the report?
- The market report presents the estimated market size of Recombinant Follitropin Beta Market by the end of forecast period. Additionally, the historical and current market size is also examined in the report.
- Based on various indicators, the Year-on-Year growth (%) and compound annual growth rate (CAGR) for the given forecast period is offered.
- An overview of the Market based on geographical scope, market segmentation and financial performance of key players is presented in the report.
- The report presents current trends in the industry and future scope of the Market in North America, Asia Pacific, Europe, Latin America and Middle East and Africa.
- The various parameters accelerating the growth of Market are incorporated in the research report.
- The report analyzes growth rate, market size and valuation of the Market during the forecast period.
What aspects regarding the regional analysis Market are included in this report?
- Geographical regions covered in the report include North America, Europe, Asia Pacific, Latin America and Middle East & Africa region.
- The report consists of detailed region-wise analysis of current and future market trends, providing information on product usage and consumption.
- The growth rate of the market in every region, including their countries over the forecast period is included in the market report.
Based on what factors are the key market players assessed in this report?
- The report offers detailed analysis of leading companies in the market across the globe.
- It provides details of the major vendors involved in the Market including Key Players
- A comprehensive overview of each company including the company profile, generated revenue, pricing of goods and the manufactured products is incorporated in the report.
- The facts and figures about market competitors along with standpoints of leading market players are presented in the report.
- The recent developments, mergers and acquisitions related to mentioned key players are provided in the market report.
What is the key information extracted from the report?
- Extensive information on factors estimated to affect the Market growth and market share during the forecast period is presented in the report.
- The report offers the present scenario and future growth prospects Market in various geographical regions.
- The competitive landscape analysis on the market as well as the qualitative and quantitative information is delivered.
- The SWOT analysis is conducted along with Porter's Five Force analysis.
- The in-depth analysis provides an insight into the Market, underlining the growth rate and opportunities offered in the business.
Request for Full Report:
About Kenneth Research:
Kenneth Research provides scheduled syndicated reports that help industry professionals and organizations decipher market trends to take significant decisions and plan strategies. We cater to a wide range of industries including healthcare & pharmaceuticals, ICT & telecom, automotive & transportation, energy & power, chemicals, FMCG & food, aerospace & defense, among others. Our research team ensures to track and analyze the industry on a regular basis to offer strategic business consultancy services on a global level. We, at Kenneth Research are adept at capturing descriptive insights on crucial topics to help our clients make their informed decisions.
Contact Us
Name : Kenneth research
Email:
Phone: +1 313 462 0609
Eli
Eli is a freelance writer and possess double graduation degree in physics and chemistry. She is an intense writer covering everything for Science and Tech to Business, Entertainment, Sports and Lifestyle.
MENAFN16062022004545010068ID1104383864
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.